- Home
- SPT vs AKRO Comparison
SPT vs AKRO Comparison
Compare SPT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPT | AKRO |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 633.9M | 4.5B |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SPT | AKRO |
|---|---|---|
| Price | $11.03 | $54.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | $26.00 | ★ $73.56 |
| AVG Volume (30 Days) | 1.1M | ★ 2.4M |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $443,750,000.00 | N/A |
| Revenue This Year | $13.30 | N/A |
| Revenue Next Year | $11.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.09 | N/A |
| 52 Week Low | $9.16 | $21.34 |
| 52 Week High | $36.30 | $58.40 |
Technical Indicators
Market Signals| Indicator | SPT | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 55.86 | 68.63 |
| Support Level | $10.50 | $54.30 |
| Resistance Level | $11.49 | $54.70 |
| Average True Range (ATR) | 0.45 | 0.17 |
| MACD | 0.11 | -0.10 |
| Stochastic Oscillator | 73.28 | 71.07 |
Price Performance
Historical ComparisonAbout SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.